Literature DB >> 22296186

Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA.

B Leticia Rodriguez1, Xinran Li, Kaoru Kiguchi, John DiGiovanni, Evan C Unger, Zhengrong Cui.   

Abstract

AIM: Previously, it was shown that treatment of tumor-bearing mice with an RNA replicase-based plasmid that produces dsRNA when transfected into tumor cells significantly inhibited the tumor growth. In the present study, the feasibility of further improving the anti-tumor activity of the RNA replicase-based plasmid by targeting it into tumors cells was evaluated. MATERIAL &
METHODS: An EGF-conjugated, polyethylene glycosylated cationic liposome was developed to deliver the RNA replicase-based plasmid, pSIN-β, into EGF receptor-overexpressing human breast cancer cells (MDA-MB-468) in vitro and in vivo.
RESULTS: Delivery of pSIN-β using the EGF receptor-targeted liposome more effectively controlled the growth of MDA-MB-468 tumors (and human epidermoid carcinoma A431 tumors) in mice than using untargeted liposome. The pSIN-β carried by the EGF receptor-targeted liposome caused the complete regression of MDA-MB-468 tumors in mice, probably due to the enhancement of its proapoptotic, antiproliferative and antiangiogenic activities. DISCUSSION: Tumor-targeted RNA replicase-based plasmids hold a strong potential in tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22296186      PMCID: PMC3523886          DOI: 10.2217/nnm.11.112

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  43 in total

1.  LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth.

Authors:  M Whitmore; S Li; L Huang
Journal:  Gene Ther       Date:  1999-11       Impact factor: 5.250

Review 2.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

Authors:  Y Yarden
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

3.  ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

Authors:  Malcolm Ranson; Lisa A Hammond; David Ferry; Mark Kris; Andrew Tullo; Philip I Murray; Vince Miller; Steve Averbuch; Judy Ochs; Charles Morris; Andrea Feyereislova; Helen Swaisland; Eric K Rowinsky
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

Review 4.  Monoclonal antibodies directed at growth factor receptors.

Authors:  J Baselga
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

5.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

6.  Molecular classification of human carcinomas by use of gene expression signatures.

Authors:  A I Su; J B Welsh; L M Sapinoso; S G Kern; P Dimitrov; H Lapp; P G Schultz; S M Powell; C A Moskaluk; H F Frierson; G M Hampton
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

7.  Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: in vitro and in vivo evaluation.

Authors:  Zhengrong Cui; Russell J Mumper
Journal:  Bioconjug Chem       Date:  2002 Nov-Dec       Impact factor: 4.774

Review 8.  Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.

Authors:  M Chawla-Sarkar; D J Lindner; Y-F Liu; B R Williams; G C Sen; R H Silverman; E C Borden
Journal:  Apoptosis       Date:  2003-06       Impact factor: 4.677

9.  Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processing.

Authors:  Erika Bohl Kullberg; Marika Nestor; Lars Gedda
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

10.  Replicase-based plasmid DNA shows anti-tumor activity.

Authors:  B Leticia Rodriguez; Zhen Yu; Woon-Gye Chung; Richard Weiss; Zhengrong Cui
Journal:  BMC Cancer       Date:  2011-03-28       Impact factor: 4.430

View more
  3 in total

1.  Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.

Authors:  B Leticia Rodriguez; Jorge M Blando; Dharmika S P Lansakara-P; Yuriko Kiguchi; John DiGiovanni; Zhengrong Cui
Journal:  Mol Pharm       Date:  2013-05-17       Impact factor: 4.939

2.  Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo.

Authors:  Qianqian Jiang; Yue Yuan; Yi Gong; Xinmei Luo; Xiaolan Su; Xueting Hu; Wen Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-25       Impact factor: 4.553

3.  A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy.

Authors:  Li Qin; Cheng-Zheng Wang; Hui-Jie Fan; Chong-Jian Zhang; Heng-Wei Zhang; Min-Hao Lv; Shu-DE Cui
Journal:  Oncol Lett       Date:  2014-08-14       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.